Cytosorbents (CTSO) Q3 2024 earnings summary

Executive summary

• Q3 2024 product sales reached $8.6 million, up 11% year-over-year, with total revenue of $9.4 million, driven by strong international direct sales and distributor network performance.

• Net loss narrowed to $2.3 million ($0.04/share) from $9.2 million in Q3 2023, with adjusted net loss improving to $4.5 million ($0.08/share).

• CytoSorb, the flagship product, generated $34 million in trailing 12-month sales, with over 250,000 devices used in 76 countries.

• Regulatory milestones achieved for DrugSorb-ATR, with FDA and Health Canada reviews underway and decisions expected in 2025, targeting a $300M+ initial addressable market.

• Cash, cash equivalents, and restricted cash totaled $12.2 million at quarter-end, with improved cash usage and ongoing cost controls.

Financial highlights

• Q3 2024 revenue was $9.4 million (+7% YoY); product sales were $8.6 million (+11% YoY); grant income declined to $0.8 million.

• Product gross margin was 61%, down from 72% last year due to planned production slowdown and manufacturing issues, with normalization expected in Q4 2024.

• Operating expenses decreased 25% year-over-year to $9.7 million, resulting in a 40% reduction in operating loss.

• Adjusted EBITDA loss improved to $3.5 million from $5.6 million in the prior year.

• Cash burn reduced to $2.7 million in Q3 2024 from $5.0 million in Q2 2024.

Outlook and guidance

• Expectation of normalized production levels and gross margins in Q4 2024, with long-term gross margin targets of 75%-80%.

• Regulatory decisions for DrugSorb-ATR in the U.S. and Canada anticipated in 2025, potentially catalyzing entry into large North American markets.

• Management expects cost-cutting and milestone-driven cash releases to fund operations through 2025 if milestones are met.